MD-Bio

What MD-Bio does

MD-Bio (legal entity MobileDetect Bio, Inc.) is a private medical equipment manufacturer founded in 2020 in Sugar Land, Texas, that designs and sells lateral flow assay drug test strips and kits for the harm reduction market. The company was launched during the COVID-19 pandemic and pivoted to opioid and synthetic drug supply testing, manufacturing single-use strips and complete kits that detect trace amounts of fentanyl, xylazine, nitazenes, medetomidine, and benzodiazepines in pills, powders, liquids, and residues. Detection thresholds range from 100 ng/mL (fentanyl) to 1,000 ng/mL (benzodiazepines), with results delivered visually in 2-5 minutes. The company also sells a Drink Spike Test Pen that screens beverages for GHB, ketamine, and benzodiazepines, targeting venue operators in addition to individual users.

The product line is built on lateral flow immunoassay chemistry and comes in two formats: strip-only SKUs and complete kits that bundle a pre-measured buffer solution tube, swab, and analysis pad. Notable product variants include a Fentanyl and Xylazine Dual-Strip Kit that combines the two most prevalent adulterant tests into a single workflow, and a unique Medetomidine strip/kit for an emerging veterinary-sedative adulterant. Technical differentiators highlighted in the company's materials include pre-measured buffer for consistent dilution, QR-code-linked instructions, and SAMHSA designation of the fentanyl strip as an approved purchase under federal harm reduction grants.

MD-Bio operates a direct-to-consumer e-commerce model through mdbio.com with toll-free phone sales support and same-day shipping for orders placed before 3pm CST. Pricing is unit-based with volume tiers, ranging from $0.75 per fentanyl strip at 100+ units to $24.95 for a five-pack of drink spike pens, with dedicated nonprofit/bulk pricing available on request. Primary customer segments are harm reduction nonprofits and individual consumers conducting personal drug safety testing, with venue operators (bars, clubs, concert venues) as a secondary segment. The company serves primarily North America with international shipping available on request. No funding rounds, institutional investors, named management, M&A activity, or revenue figures are disclosed in the available data.

Name

MD-Bio

Legal name

MobileDetect Bio, Inc.

Website

https://mdbio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

MD-Bio (MobileDetect Bio, Inc.) manufactures lateral flow drug test strips and kits for fentanyl, xylazine, nitazenes, medetomidine, and benzodiazepines, selling direct-to-consumer and to harm reduction organizations through its e-commerce site.

Ownership category

akta.pro rank

Product category

Diagnostic Test Strips

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industry

Pharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring (HLAFALAN)

Keywords

• Drug test strips
• Lateral flow assays
• Harm reduction supplies
• Substance detection kits
• Fentanyl test strips

Headquarters

HQ city

Sugar Land

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Drug Test Strip Sales: Sale of individual test strips and complete test kits for fentanyl, xylazine, nitazenes, benzodiazepines, medetomidine, and drink spike detection. Products sold at various price points with volume-based tiered pricing.
2. Bulk/Nonprofit Pricing: Special pricing offered for bulk orders and nonprofit organizations serving harm reduction communities

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

MD-Bio manufactures and sells lateral flow assay drug-detection test strips and kits for substances including fentanyl, xylazine, nitazenes, benzodiazepines, and medetomidine, as well as a drink-spike detection pen and a BCC19 (COVID-19) antigen test. Products are sold directly to individual consumers, harm reduction organizations, and venue operators via the company's website and phone sales, with volume-tiered pricing.

Product overview

MD-Bio provides a portfolio of lateral flow assay drug test strips and kits for harm reduction applications. The product line consists of two main formats: test strips (strip-only, requiring separate buffer and swab) and test kits (complete with strip, pre-filled buffer tube, swab, and analysis pad). Core products cover five substance categories: Fentanyl, Xylazine, Nitazene, Medetomidine, and Benzodiazepines. The portfolio also includes a multi-substance Fentanyl and Xylazine Dual-Strip Kit combining both tests in one package, and a Drink Spike Test Pen for beverage safety. All products use lateral flow immunoassay technology to detect specific compounds in pills, powders, liquids, and residues with detection thresholds in the ng/mL range and results typically within 2-3 minutes.

Differentiator

Problem solved

Functional benefit

Products and services

• Fentanyl Test Strip

Quantifiable outcome

• Results available in 2-3 minutes for rapid decision-making
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• SAMHSA (Substance Abuse and Mental Health Services Administration)coreOthers · 7 April 2021SAMHSA designated MD-Bio Fentanyl Test Strips as an approved test for purchase with SAMHSA grant funds. This regulatory approval allows grantees to use federal funding to purchase MD-Bio products for harm reduction programs.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• BTNX Inc. Canadian biotechnology company best known for its Rapid Response line of fentanyl and drug test strips; the closest direct competitor to MD-Bio in lateral-flow harm reduction assays sold through similar harm reduction and DTC channels.
• DanceSafe: Nonprofit that supplies fentanyl test strips, reagent test kits, and other drug-checking tools to the nightlife and harm reduction communities, competing head-to-head with MD-Bio for harm reduction organization buyers.
• Bunk Police: Sells consumer-facing drug-checking kits including fentanyl and adulterant test strips at music festivals and through online channels, competing directly for individual consumer and harm reduction customers.
• FentCheck (by FentCheck LLC): Dedicated fentanyl test strip brand sold via e-commerce to consumers and harm reduction programs, with comparable unit pricing and DTC distribution to MD-Bio.
• Wisebatch: Sells fentanyl and multi-drug test strips via online storefronts to consumers and harm reduction organizations, with similar pricing tiers and product breadth to MD-Bio's catalog.

Regional players

• ProTest Kit UK: UK-based harm reduction organization distributing fentanyl and adulterant test strips across Europe, comparable in product mix but operating in a different geography from MD-Bio's North American base.

Others

• DetectaChem (parent brand presence): Mobile detection/chemistry brand whose social media channels (Facebook, LinkedIn, Twitter, Instagram, YouTube) are listed as MD-Bio's, suggesting an affiliated or shared-platform relationship with broader analytical chemistry detection products.
• Adaptive Biotechnologies: Listed for adjacency in immunoassay and diagnostic technology development; while focused on immune profiling rather than drug detection, it represents the broader diagnostic ecosystem MD-Bio operates within.

Broad incumbents

• Abbott Laboratories: Global diagnostics leader with a broad lateral-flow, immunoassay, and rapid test portfolio (including toxicology and substance detection); a broad incumbent whose resources and distribution could enter MD-Bio's niche.
• Thermo Fisher Scientific: Major life sciences and analytical instruments company with lateral flow, immunoassay reagents, and clinical chemistry capabilities; represents both a potential competitor and supplier of assay components relevant to MD-Bio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/DetectaChem
• YouTubeyoutube.com/playlist?list=PLtWAT2e2IHOIQOnPqBPtZngDZY1O_BWiZ
• Facebookfacebook.com/detectachem
• LinkedInlinkedin.com/company/md-bio-incorporated
• Instagraminstagram.com/detectachem

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MD-Bio